These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2694424)

  • 1. Plasma von Willebrand factor proteolysis in patients with chronic myeloproliferative disorders: no possibility of ex vivo degradation by calcium-dependent proteases.
    Tatewaki W; Takahashi H; Takakuwa E; Wada K; Shibata A
    Thromb Res; 1989 Oct; 56(2):191-9. PubMed ID: 2694424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced ex vivo proteolysis of plasma von Willebrand factor in disseminated intravascular coagulation.
    Takahashi H; Tatewaki W; Wada K; Niwano H; Shibata A
    Blood Coagul Fibrinolysis; 1992 Oct; 3(5):583-8. PubMed ID: 1450324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired von Willebrand Disease in Patients with Chronic Myeloproliferative Disorders.
    Tatewaki W; Shibata A
    Leuk Lymphoma; 1989; 1(1):51-7. PubMed ID: 27456408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimeric composition of plasma von Willebrand factor in chronic myeloproliferative disorders.
    Tatewaki W; Takahashi H; Shibata A
    Clin Lab Haematol; 1988; 10(4):417-25. PubMed ID: 3150698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIa von Willebrand's disease.
    Gralnick HR; Williams SB; McKeown LP; Maisonneuve P; Jenneau C; Sultan Y; Rick ME
    Proc Natl Acad Sci U S A; 1985 Sep; 82(17):5968-72. PubMed ID: 2994057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome.
    Budde U; Dent JA; Berkowitz SD; Ruggeri ZM; Zimmerman TS
    Blood; 1986 Dec; 68(6):1213-7. PubMed ID: 3535924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis.
    López-Fernández MF; López-Berges C; Martín R; Pardo A; Ramos FJ; Batlle J
    Thromb Haemost; 1987 Aug; 58(2):753-7. PubMed ID: 3499682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation.
    Federici AB; Elder JH; De Marco L; Ruggeri ZM; Zimmerman TS
    J Clin Invest; 1984 Dec; 74(6):2049-55. PubMed ID: 6239876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte proteases do not process endothelial cell-derived unusually large von Willebrand factor multimers to plasma vWF in vivo.
    Phillips MD; Vu C; Nolasco L; Moake JL
    Am J Hematol; 1991 Jun; 37(2):80-3. PubMed ID: 2069167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired von Willebrand syndrome in a myeloproliferative disorder. Case 6.
    Baud P; Tobler A; Lämmle B; Alberio L
    Hamostaseologie; 2003 Aug; 23(3):121-4. PubMed ID: 12923581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Moake JL; McPherson PD
    Am J Med; 1989 Sep; 87(3N):9N-15N. PubMed ID: 2486537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered von Willebrand factor subunit proteolysis and multimer processing associated with the Cys2362Phe mutation in the B2 domain.
    Casonato A; De Marco L; Gallinaro L; Sztukowska M; Mazzuccato M; Battiston M; Pagnan A; Ruggeri ZM
    Thromb Haemost; 2007 Apr; 97(4):527-33. PubMed ID: 17393013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
    Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
    Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.
    Mohri H
    J Thromb Thrombolysis; 2003 Jun; 15(3):141-9. PubMed ID: 14739623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
    Stufano F; Baronciani L; Pagliari MT; Franchi F; Cozzi G; Garcia-Oya I; Bucciarelli P; Boscarino M; Peyvandi F
    J Thromb Haemost; 2015 Oct; 13(10):1806-14. PubMed ID: 26206100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein.
    He S; Cao H; Magnusson CG; Eriksson-Berg M; Mehrkash M; Schenck-Gustafsson K; Blombäck M
    Thromb Res; 2001 Aug; 103(3):241-8. PubMed ID: 11672586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis.
    Federici AB; Berkowitz SD; Lattuada A; Mannucci PM
    Blood; 1993 Feb; 81(3):720-5. PubMed ID: 8427964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.